Video

What Lessons Have Been Learned from High Cost Hepatitis C Drugs?

Author(s):

Davy James, Managing Editor

Marc O'Connor, Chief Operating Officer of Curant Health, discusses the main takeaways from the impact of hepatitis C drugs on specialty pharmacy.

Marc O'Connor, Chief Operating Officer of Curant Health, discusses the main takeaways from the impact of hepatitis C drugs on specialty pharmacy.

This video was recorded courtesy of Armada Health Care at the 2015 Armada Specialty Pharmacy Summit in Las Vegas, Nevada.

Related Videos
Related Content
FDA Approves Expanded Use for Trikafta in Cystic Fibrosis
December 20th 2024

FDA Approves Expanded Use for Trikafta in Cystic Fibrosis

Aislinn Antrim, Assistant Managing Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

Mounjaro tirzepatide GLP-1 receptor agonist vial | Image Credit: © Cynthia - stock.adobe.com
December 20th 2024

FDA Affirms Decision on Tirzepatide Shortage Resolved, Sets Transition Period for Compounding

Alexandra Gerlach, Associate Editor
Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer
October 28th 2024

Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer

ASHP Midyear: Automated Compounding Workflows and Comprehensive Record-Keeping Reduce Errors
December 19th 2024

ASHP Midyear: Automated Compounding Workflows and Comprehensive Record-Keeping Reduce Errors

Biosimilars, Digital Tool, Patients, Health Care Professionals, Education | Image Credit: © Pixels Hunter | stock.adobe.com
December 17th 2024

Investigators Develop Training Tool to Improve Prescriber-Patient Communication About Biosimilars

Ashley Gallagher, Associate Editor